The Purpose is to Evaluate Visual Acuity for Distance, Intermediate and Near and Additionally Contrast Sensitivity at 25% and 10% of Illumination After Implantation of Trifocal IOL, Extended Range of Vision IOL, Bifocal IOL With Low Addition and Monofocal IOL
NCT ID: NCT07008768
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
131 participants
INTERVENTIONAL
2018-01-01
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Evaluate the Visual Performance of Three Multifocal IOLs
NCT02990689
Visual Function of Enhanced Monofocal Intraocular Lenses
NCT07262021
A Comparison of the Visual Performance of Trifocal Versus Extended Depth of Focus Intraocular Lenses
NCT03726606
Head-to-Head Comparison of Five Enhanced Depth of Focus IOLs and One Monofocal IOL
NCT07051720
Study on Visual Performance of a Monofocal Intraocular Lens
NCT04740788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study was designed to include 4 groups, each comprising 50 participants. Eligible participants were those aged 45 years or older and present with hyperopia ranging from +0.50 dioptres (D) to +5.00 D, and astigmatism of up to +1.00 D. Participants with refractive errors must exhibit a best-corrected visual acuity (BCVA) of ≥0.05 Logarithm of the Minimum Angle of Resolution (LogMAR). For those with cataracts, inclusion requires a BCVA of ≥0.7 LogMAR, contingent upon cataract severity. Participants with BCVA \<0.05 LogMAR were enrolled only after the exclusion of low vision, as confirmed by prior ophthalmological records.
All patients underwent a comprehensive preoperative ophthalmologic evaluation. This included slit-lamp bio microscopy of the anterior segment and dilated fundus examination. Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), as well as manifest and cycloplegic refractions were recorded. Corneal tomography was performed to assess the topography of both the anterior and posterior corneal surfaces, as well as corneal thickness. Wavefront aberrometry (Luneau Visionix L80 Wave+, Visionix, Prunay-le-Gillon, France), was conducted to evaluate higher-order aberrations. Pupil size was measured under photopic, mesopic, and scotopic conditions using a pupillometer (Peramis, CSO, Italy). Specular microscopy (Perseus specular microscope, CSO, Firenze, Italy), was employed to determine corneal endothelial cell density. Additional assessments included determination of ocular dominance, evaluation of ocular motility, and assessment of tear film stability using the Schirmer test and Tear Break-Up Time (TBUT) test. Contrast sensitivity (CS) at 10% and 25% illumination was also measured.
Phacoemulsification was performed using the Infinity Vision System (Abbott Medical Optics, WhiteStar Signature Phacoemulsification System). Surgical parameters, including phaco power, vacuum level, pulse mode, oscillation, and infusion bottle height, were adjusted according to the specific phase of the procedure. All surgeries were performed by a single experienced surgeon employing a standardized micro coaxial technique. Corneal incisions measuring 2.7 mm were created along the steepest meridian; in rare cases where intraoperative challenges were encountered, the incision was extended.
Following successful completion of anterior capsulorhexis and lens phacoemulsification, a foldable intraocular lens (IOL) was implanted into the capsular bag via the main incision using the Acrijet Blue injector (VSY Biotechnology, Amsterdam, Netherlands). Residual viscoelastic material was thoroughly removed by irrigation and aspiration. All corneal incisions were self-sealing and did not require suturing. At the conclusion of the procedure, an antibiotic drop was instilled intraocularly, and antibiotic ointment was applied to the conjunctival sac. Maxitrol eyedrops (Alcon, Fort Worth, Texas), a neomycin, polymyxin B sulphates, and dexamethasone ophthalmic suspension were prescribed for application after the surgery. At first postoperative day drops were administered every hour, then four times per days in first postoperative week, and then gradually tapered for next three weeks.
Patients underwent follow-up evaluations at 1 week, 1, 6, and 12 months postoperatively. During each examination, the anterior eye segment was thoroughly assessed and documented. Uncorrected and corrected visual acuity was measured at multiple working distances (6m, 80 cm and 35 cm). Additionally, refractive status was evaluated by quantifying spherical and cylindrical corrections. Contrast sensitivity was assessed under illumination levels of 10% and 25%, and higher-order aberrations of coma and SA (spherical aberration) were measured to determine optical quality.
Data from treated eyes were analysed. Details of visual acuities, sphere and cylinder refraction, contrast sensitivity at 10% and 25% illumination, and higher-order aberrations were recorded and stored on Excel spreadsheets (Microsoft, Redmond, WA) during the monitoring of the subjects. Descriptive statistics, including minimum and maximum values, means, standard deviations, medians, and interquartile ranges, were used for preliminary variable characterization by groups. Prior to inferential analyses, the Kolmogorov-Smirnov test was applied to assess the normality of variable distributions, which is a prerequisite for parametric tests such as ANOVA and the t-test. As the Kolmogorov-Smirnov test indicated non-normal distribution for the variables, nonparametric statistical methods were employed throughout subsequent analyses. Specifically, the Friedman test was utilized to evaluate differences across multiple measurement time points within groups. When the Friedman test revealed statistically significant differences, pairwise comparisons were conducted using the Wilcoxon signed-rank test to identify specific time points exhibiting significant changes. For comparisons between the two independent groups-patients implanted with a new generation multifocal intraocular lens and those receiving a monofocal lens implant-the Mann-Whitney U test was applied. All statistical tests were performed at a significance level of 0.05 (95% confidence interval).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 3 - BIFOCAL IOL
The total number of patients who underwent cataract surgery or refractive lens exchange surgery with bifocal IOL with low addition implantation was thirty-four of the mean (±sd; range) age 59.94 (±9.1, 45-71).
Cataract surgery and refractive lens exchange surgery
Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
BIFOCAL IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition
Group 4 - MONOFOCAL IOL
The total number of patients who underwent cataract surgery or refractive lens exchange surgery with monofocal IOL implantation was thirty-two of the mean (±sd; range) age 61.33 (±8.7, 45-74), were recruited as controls.
Cataract surgery and refractive lens exchange surgery
Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
MONOFOCAL IOL
Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL
Group 1 - TRIFOCAL IOL
The total number of patients who underwent cataract surgery or refractive lens exchange surgery with trifocal IOL implantation was thirty of the mean (±sd; range) age 57.23 (±6.1, 45-69).
Cataract surgery and refractive lens exchange surgery
Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
TRIFOCAL IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal
Group 2 - EROV
The total number of patients who underwent cataract surgery or refractive lens exchange surgery with extended range of vision IOL implantation was thirty-five of the mean (±sd; range) age 59.12 (±5.4, 45-71).
Cataract surgery and refractive lens exchange surgery
Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
EROV IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract surgery and refractive lens exchange surgery
Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
TRIFOCAL IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal
EROV IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)
BIFOCAL IOL
1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition
MONOFOCAL IOL
Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hyperopic correction ranging from +0.50 D to +5.00 D, and astigmatism of up to +1.00 D
* Best corrected visual acuity of ≥0.05 LogMAR
Exclusion Criteria
* Glaucoma
* Fuchs' endothelial dystrophy or other corneal diseases (corneal degeneration and dystrophy)
* Zonular weakness or subluxated lens
* Systemic autoimmune and rheumatic disease
* Insulin dependent diabetes
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Eye Hospital Svjetlost
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mateja Jagic
MD, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univestity Eye Hospital Svjetlost
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KS001-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.